Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Transgene S.A. (TNG.PA)
Illkirch-Graffenstaden, FR
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.12% | +0.60% | +11.93% | -6.18% | -16.50% | -13.02% | -14.97% | -53.82% | -72.98% | -69.30% | -98.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-92.3% Q4'25: -98.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+10.3% Q4'25: -73.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-8,199.6% Q4'25: -46,619.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-8,381.6% Q4'25: -44,707.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-344.1% Q4'25: -544.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+23.7% Q4'25: +57.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q4'25: -0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.47M
est: 9.40M (-84.4%)
|
2.35M
est: 10.31M (-77.2%)
|
2.10M
est: 8.12M (-74.2%)
|
1.34M
est: 15.49M (-91.4%)
|
13.30M
est: 10.80M (+23.1%)
|
2.98M
est: 48.58M (-93.9%)
|
9.99M
est: 11.78M (-15.1%)
|
3.13M
est: 8.90M (-64.9%)
|
7.90M
est: 6.49M (+21.7%)
|
6.35M
est: 8.67M (-26.7%)
|
490.0K
est: 9.27M (-94.7%)
|
8.15M
8.15M – 8.15M
-12.1% YoY
|
8.55M
8.55M – 8.55M
+4.9% YoY
|
58.65M
57.93M – 59.37M
+586.0% YoY
|
25.50M
25.50M – 25.50M
-56.5% YoY
|
22.06M
22.06M – 22.06M
-13.5% YoY
|
| EBITDA |
-34.72M
est: -9.40M (-269.4%)
|
-20.38M
est: -10.31M (-97.7%)
|
-29.50M
est: -8.12M (-263.3%)
|
2.85M
est: -15.49M (+118.4%)
|
-23.73M
est: -10.80M (-119.8%)
|
-14.13M
est: -48.58M (+70.9%)
|
-23.55M
est: -11.78M (-100.0%)
|
-30.33M
est: -8.90M (-240.8%)
|
-28.44M
est: -6.49M (-337.9%)
|
-26.65M
est: -8.67M (-207.3%)
|
-39.77M
est: -9.27M (-328.9%)
|
-8.15M
-8.15M – -8.15M
+12.1% YoY
|
-8.55M
-8.55M – -8.55M
-4.9% YoY
|
-58.65M
-59.37M – -57.93M
-586.0% YoY
|
-25.50M
-25.50M – -25.50M
+56.5% YoY
|
-22.06M
-22.06M – -22.06M
+13.5% YoY
|
| EBIT |
-37.36M
est: -9.40M (-297.4%)
|
-23.43M
est: -10.31M (-127.2%)
|
-31.20M
est: -8.12M (-284.1%)
|
9.06M
est: -15.49M (+158.5%)
|
-25.40M
est: -10.80M (-135.2%)
|
-15.89M
est: -48.58M (+67.3%)
|
-19.07M
est: -11.78M (-62.0%)
|
-32.00M
est: -8.90M (-259.6%)
|
-30.01M
est: -6.49M (-362.1%)
|
-27.93M
est: -8.67M (-222.1%)
|
-41.07M
est: -9.27M (-342.9%)
|
-8.15M
-8.15M – -8.15M
+12.1% YoY
|
-8.55M
-8.55M – -8.55M
-4.9% YoY
|
-58.65M
-59.37M – -57.93M
-586.0% YoY
|
-25.50M
-25.50M – -25.50M
+56.5% YoY
|
-22.06M
-22.06M – -22.06M
+13.5% YoY
|
| Net Income |
-46.37M
est: -131.13M (+64.6%)
|
-25.21M
est: -71.27M (+64.6%)
|
-32.27M
est: -66.04M (+51.1%)
|
8.03M
est: -26.54M (+130.2%)
|
-18.80M
est: -37.33M (+49.6%)
|
-18.45M
est: 39.53M (-146.7%)
|
-20.00M
est: -35.39M (+43.5%)
|
-32.81M
est: -33.43M (+1.8%)
|
-22.33M
est: -32.68M (+31.7%)
|
-33.97M
est: -39.14M (+13.2%)
|
-37.52M
est: -17.58M (-113.4%)
|
-20.21M
-20.21M – -20.21M
-14.9% YoY
|
-26.70M
-26.70M – -26.70M
-32.1% YoY
|
-5.05M
-5.05M – -5.05M
+81.1% YoY
|
-15.88M
-15.88M – -15.88M
-214.3% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
2.70M
est: 4.79M (-43.7%)
|
2.20M
est: 5.26M (-58.2%)
|
2.40M
est: 4.14M (-42.1%)
|
3.50M
est: 7.90M (-55.7%)
|
7.13M
est: 5.51M (+29.5%)
|
2.32M
est: 24.78M (-90.7%)
|
2.59M
est: 6.01M (-56.8%)
|
3.22M
est: 4.54M (-29.0%)
|
3.82M
est: 9.73M (-60.7%)
|
3.7K
est: 12.99M (-100.0%)
|
2.80M
est: 13.89M (-79.8%)
|
12.21M
12.21M – 12.21M
-12.1% YoY
|
12.80M
12.80M – 12.80M
+4.9% YoY
|
87.84M
86.75M – 88.92M
+586.0% YoY
|
38.19M
38.19M – 38.19M
-56.5% YoY
|
33.04M
33.04M – 33.04M
-13.5% YoY
|
| EPS |
-1.20
est: -1.12 (-6.8%)
|
-0.45
est: -0.61 (+26.3%)
|
-0.51
est: -0.57 (+9.9%)
|
0.13
est: -0.23 (+157.1%)
|
-0.23
est: -0.32 (+28.1%)
|
-0.22
est: 0.34 (-164.9%)
|
-0.22
est: -0.30 (+27.5%)
|
-0.33
est: -0.34 (+2.0%)
|
-0.22
est: -0.23 (+2.9%)
|
-0.29
est: -0.27 (-6.9%)
|
-0.26
est: -0.12 (-113.4%)
|
-0.14
-0.14 – -0.14
-14.9% YoY
|
-0.19
-0.19 – -0.19
-32.1% YoY
|
-0.04
-0.04 – -0.04
+81.1% YoY
|
-0.11
-0.11 – -0.11
-214.3% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alessandro Riva | Chief Executive Officer & Chairman of the Board | 840.0K | — |
| Christophe Ancel | Vice President, Chief Quality Officer & Qualified Pharmacist | 183.0K | male |
| Emmanuelle Dochy | Vice President of Medical Affairs & Chief Medical Officer | — | female |
| Feriel Marin | Interim Chief Quality Officer | — | female |
| Gaelle Stadtler | Vice President & Director of Human Resources | — | female |
| James Wentworth | Vice President & Chief Business Officer | — | male |
| John Felitti | Vice President, General Counsel & Corporate Secretary | — | male |
| Katell Bidet Huang | Head of Translational Medicine | — | — |
| Lucie Larguier | Vice President & Chief Financial Officer | — | female |
| Maurizio Ceppi | Chief Scientific Officer | — | — |
| Simone Silva Steiner | Chief Technical Officer | — | — |
| Christelle Schwoerer | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TNG.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
